| __timestamp | Bristol-Myers Squibb Company | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4534000000 | 79696000 |
| Thursday, January 1, 2015 | 5920000000 | 93236000 |
| Friday, January 1, 2016 | 4940000000 | 150842000 |
| Sunday, January 1, 2017 | 6411000000 | 150643000 |
| Monday, January 1, 2018 | 6345000000 | 150252000 |
| Tuesday, January 1, 2019 | 6148000000 | 140804000 |
| Wednesday, January 1, 2020 | 11143000000 | 34236000 |
| Friday, January 1, 2021 | 10195000000 | 35672000 |
| Saturday, January 1, 2022 | 9509000000 | 66607000 |
| Sunday, January 1, 2023 | 9299000000 | 76363000 |
| Monday, January 1, 2024 | 11159000000 | 79048000 |
Data in motion
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Bristol-Myers Squibb has consistently increased its R&D budget, peaking in 2020 with a 145% rise from 2014 levels. This commitment underscores their strategy to maintain a competitive edge through innovation.
Conversely, Halozyme's R&D spending has seen fluctuations, with a notable dip in 2020. Despite this, their investment strategy remains focused, with a 10% increase in 2023 compared to 2014.
These insights reveal the diverse strategies companies employ to navigate the competitive pharmaceutical industry, highlighting the importance of R&D in driving future success.
Analyzing R&D Budgets: Bristol-Myers Squibb Company vs Teva Pharmaceutical Industries Limited
Bristol-Myers Squibb Company or Insmed Incorporated: Who Invests More in Innovation?
Bristol-Myers Squibb Company vs Sarepta Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Bristol-Myers Squibb Company vs Opthea Limited
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Axsome Therapeutics, Inc.
R&D Insights: How Bristol-Myers Squibb Company and TG Therapeutics, Inc. Allocate Funds
Analyzing R&D Budgets: Bristol-Myers Squibb Company vs Xenon Pharmaceuticals Inc.
Research and Development Investment: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Research and Development Expenses Breakdown: United Therapeutics Corporation vs Halozyme Therapeutics, Inc.
Research and Development Investment: Jazz Pharmaceuticals plc vs Halozyme Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Viridian Therapeutics, Inc.